AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)
31.3.2023 19:00:00 EEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
Contact information
James Rock jimrock@aribiousa.com
AriBio USA Branch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nordson EFD Launches PICO Pµlse XP HV Jetting System to Meet Assembly Market Demand for Dispensing High-Viscosity Materials9.11.2026 17:00:00 EET | Press release
Nordson EFD,a Nordson company (NASDAQ: NDSN), today announced the launch of its PICO Pµlse® XP HV jetting system designed for extremely precise (XP) assembly applications utilizing high-viscosity (HV) materials like thick silicones, greases, and UV-cure adhesives. New formulations are rapidly entering the industrial marketplace due to evolutionary new product development across multiple industries including electronics, medical, and automotive. Nordson leveraged its core competencies and time-tested structural architecture to innovate the piezoelectric jetting system for non-contact precision dispensing of this emerging genre of viscous materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921406991/en/ Caption 1: Engineered for performance, the PICO Pμlse XP HV jetting system excels in demanding applications, such as optical bonding adhesives and precise one drop fill. The PICO Pµlse XP HV jet valve is automation rea
Tashkent Makes History with Central Asia’s First Golden Globes Gala9.11.2026 15:42:00 EET | Press release
Tashkent hosted the inaugural Golden Globes Silk Road Tribute Gala, bringing together internationally recognised actors, filmmakers and cultural figures from Central Asia, the Caucasus and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109918777/en/ Tashkent Makes History with Central Asia’s First Golden Globes Gala (Photo credit: © Organising Committee of the Golden Globes Silk Road Tashkent) Guests of honour included Otabek Umarov, First Deputy Chairman of the National Olympic Committee of Uzbekistan, Vice President of the Olympic Council of Asia and Member of the FIA Senate, and Shakhnoza Mirziyoyeva, First Deputy Director of the National Agency for Social Protection, First Deputy Chairman of the National Paralympic Committee of Uzbekistan and Member of the World Aquatics Executive Bureau. The event marked the first edition of the Golden Globes Silk Road initiative, establishing Tashkent as the launch city for
Latifa bint Mohammed Inaugurates ISEA20269.11.2026 15:30:00 EET | Press release
Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority, inaugurated the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), held under the theme ‘ELYAH: Constellating Place, Data, and Identity.’ Bringing together artists, researchers and innovators from around the world, the symposium, in its largest-ever edition, explores how art, science and technology can expand creative expression, deepen cultural understanding, and shape the future of electronic and emerging art. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109319593/en/ Burj Khalifa lights up to celebrate the opening of ISEA2026 Dubai (Photo: AETOSWire) Her Highness marked the inauguration by launching the interactive ELYAH show at ARTE MUSEUM Dubai. Inspired by Dubai’s celestial heritage, the experience combined light, music, performance and digital technology to explore the relations
Muslim World League’s “Minhaj” App Participates in Hajj Conference and Exhibition 2026 in Jeddah9.11.2026 15:04:00 EET | Press release
The “Minhaj” app, developed by the Muslim World League (MWL), is participating in the sixth edition of the Hajj Conference and Exhibition 2026, which commenced today in Jeddah under the patronage of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud (may Allah protect him). Organized by the Ministry of Hajj and Umrah in cooperation with the Pilgrim Experience Program, one of the programs of Saudi Vision 2030, the event is being held from November 8 to 11 at the Jeddah Superdome under the theme “From Makkah to the World.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109411972/en/ The pavilion of the Muslim World League (MWL) at the sixth edition of the Hajj Conference and Exhibition 2026 in Jeddah, Saudi Arabia. (Photo: AETOSWire) Minhaj’s participation in this international event aims to introduce its integrated Islamic digital ecosystem, launched from Makkah to serve Muslims worldwide. The app off
CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 14:44:00 EET | Press release
CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom